Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9H2H8
UPID:
PPIL3_HUMAN
Alternative names:
Cyclophilin J; Cyclophilin-like protein PPIL3; Rotamase PPIL3
Alternative UPACC:
Q9H2H8; Q86WF9; Q96IA9; Q9BXZ1
Background:
Peptidyl-prolyl cis-trans isomerase-like 3, known by alternative names such as Cyclophilin J, Cyclophilin-like protein PPIL3, and Rotamase PPIL3, plays a crucial role in protein folding. It specifically accelerates the folding of proteins by catalyzing the cis-trans isomerization of proline imidic peptide bonds in oligopeptides, a process essential for proper protein function. This enzyme may also have a role in pre-mRNA splicing, indicating its multifaceted involvement in cellular processes.
Therapeutic significance:
Understanding the role of Peptidyl-prolyl cis-trans isomerase-like 3 could open doors to potential therapeutic strategies. Its pivotal function in protein folding and possible involvement in pre-mRNA splicing make it an intriguing target for drug discovery, aiming to address diseases where protein misfolding or splicing errors are contributing factors.